Heparin in Sepsis: Current Clinical Findings and Possible Mechanisms
Author Information
Author(s): Yu Sihan, Chi Yawen, Ma Xiaochun, Li Xu
Primary Institution: Department of Critical Care Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Hypothesis
Can heparin therapy improve outcomes in sepsis patients?
Conclusion
Heparin may reduce mortality in sepsis patients, particularly those with severe disease and disseminated intravascular coagulation.
Supporting Evidence
- Subgroup analyses suggest that heparin therapy may reduce mortality in sepsis patients with disseminated intravascular coagulation.
- Meta-analyses indicate that heparin can decrease 28-day mortality in severe sepsis patients.
- Clinical studies show that heparin has both anticoagulant and non-anticoagulant effects that may benefit sepsis patients.
Takeaway
Heparin is a medicine that helps people with sepsis, a serious infection, by preventing blood clots and helping them get better.
Methodology
This review analyzes data from various clinical studies, including randomized controlled trials and meta-analyses, to evaluate the effects of heparin in sepsis.
Potential Biases
Potential biases may arise from the heterogeneity of sepsis patients and the variability in study designs.
Limitations
The review highlights the lack of definitive evidence from large randomized controlled trials and the complexity of sepsis as a clinical syndrome.
Participant Demographics
The studies included adult patients diagnosed with sepsis, with varying severity and comorbidities.
Statistical Information
P-Value
<0.05
Confidence Interval
95%CI [0.72, 0.94]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website